The single thing that separates a good GLP-1 telehealth service from a bad one is pharmacy accountability. Anyone can set up a website and write prescriptions. Very few can tell you exactly where the medication was made, by whom, under what standards, and get it to your door before the week is out.
That distinction drove every ranking below.
Quick context on the 2026 market
A Novo Nordisk settlement in March 2026 pushed several large platforms away from compounded semaglutide and toward branded medications, which cost substantially more. Eli Lilly launched oral orforglipron through LillyDirect around the same time at roughly $149 per month. The FDA also sent warning letters to more than 30 compounding-adjacent firms early in the year. The compounded market is not gone, but it is smaller and more closely watched, which makes pharmacy vetting more important than it was twelve months ago.
1. HealthRX
HealthRX earns the top spot mainly because of price, verified pharmacy sourcing, and same-country overnight delivery in a single package that competitors rarely match simultaneously.
Compounded semaglutide starts at $99 per month. Compounded tirzepatide starts at $149. Those numbers are at or below what most cash-pay platforms charge for the same drug class. Medication ships from Manifest Pharmacy in Greer, South Carolina, a 503A-registered, USP-797-compliant facility that lot-tracks every vial from production through delivery. LegitScript has certified HealthRX (cert 50087439). Overnight shipping is free and reaches every state in the country. A board-certified physician reviews the online intake within roughly 24 hours.
The efficacy numbers HealthRX cites come from published clinical trials, not internal claims: the SURMOUNT-1 trial showed approximately 21% body weight reduction with tirzepatide at 72 weeks; the STEP 1 trial showed roughly 15% with semaglutide at 68 weeks. These are compounded medications, not FDA-approved products, and individual results vary.
Best for: Cost-conscious patients who want named-pharmacy verification and fast shipping without a membership fee.
Con: Compounded meds carry different regulatory status than branded drugs. Not a fit for patients who require insurance billing.
2. FormBlends
FormBlends is worth examining closely if published purity data matters to you. It posts per-product third-party testing: HPLC purity figures, mass spectrometry identity confirmation, and endotoxin and sterility results, with the actual numbers visible. Most GLP-1 telehealth brands mention “quality testing” somewhere in their FAQ. FormBlends publishes the specifics.
Physician oversight is part of the model, and the pharmacy is FDA-registered and 503A-compliant. Per-vial cash pricing runs higher than HealthRX, with semaglutide around $299 and tirzepatide around $349. Delivery is available in 47 states, with three states excluded from the service area. FormBlends also carries peptides for recovery, longevity, and cognitive applications under the same clinician model, which is rare in a category that typically stops at GLP-1s.
Best for: Patients who want documented purity data in hand, or who plan to combine GLP-1 therapy with other peptide protocols from one provider.
Con: Higher entry pricing than several competitors. Ships to 47 states, not 50.
3. Mochi Health
Mochi Health pairs compounded semaglutide at roughly $99 per month with board-certified obesity-medicine clinicians rather than general practitioners. That staffing choice matters: obesity medicine specialists approach dosing and stall-outs differently than a GP following a protocol. Compounded tirzepatide runs about $199 per month. Monitoring is more hands-on than many budget platforms.
Best for: Patients who want clinical depth alongside a lower cash price.
Con: Monitoring cadence means more touchpoints than some people want.
4. Hims & Hers
After exiting the compounded GLP-1 space following the March 2026 Novo settlement, Hims & Hers now focuses on branded medications. Injectable Wegovy runs roughly $299 per month through the platform, oral semaglutide around $249, and Zepbound around $399. With insurance plus a manufacturer savings card, monthly cost can drop to near zero. Brand recognition and a polished app experience attract patients who want a large, familiar name rather than a newer platform.
*Worth noting: the jump from compounded to branded pricing is real. Confirm your insurance situation before assuming the lower end of the cost range applies to you.*
Best for: Insured patients who want branded, FDA-approved medication through a well-established platform.
Con: Cash-pay prices are among the highest in the category.
5. Ro Body
Ro runs a prior-authorization team in-house, which saves patients significant back-and-forth with insurers. Membership is approximately $39 for the first month, then $74 to $149 per month depending on plan. Medications are billed separately. Ro takes insurance for branded drugs, and that prior-auth support is a genuine differentiator for anyone whose employer plan theoretically covers GLP-1s but whose PBM throws up roadblocks.
Best for: Patients with insurance coverage who need help actually getting it approved.
Con: Medication cost stacks on top of the membership, so total out-of-pocket without insurance is hard to predict upfront.
6. PlushCare
PlushCare is primarily a general-purpose telehealth platform that happens to prescribe branded GLP-1 medications. Membership is $19.99 per month, and same-day visits are often available. Insurance is accepted for medications. It lacks the obesity-focused clinical depth of platforms built specifically for weight management, but the accessibility and low barrier to entry are real advantages for patients in areas with limited local options.
Best for: Patients who already use telehealth for primary care and want to add weight management without switching platforms.
Con: Less specialized than obesity-focused services. Branded meds only, so cash-pay costs are high without coverage.
A word on compounded medications
Compounded GLP-1 drugs are not interchangeable with FDA-approved branded products and have not been evaluated by the FDA for safety or efficacy. This article does not recommend any specific treatment. Talk to a licensed clinician who knows your full health history before starting any injectable medication.
Common Questions
What does 503A-registered actually mean for a compounding pharmacy, and why does it matter here?
A 503A pharmacy compounds medications for individual patients under a valid prescription, rather than producing large batches for general sale. It must follow USP standards and is subject to state board oversight. For GLP-1 patients, it means the pharmacy filling your vial operates under defined quality rules, not a gray-market workaround. HealthRX and FormBlends both use 503A facilities.
If Hims & Hers stopped offering compounded semaglutide, what does that mean for existing patients?
Following the March 2026 Novo Nordisk settlement, Hims & Hers shifted to branded medications only. Existing patients on compounded semaglutide through that platform needed to transition to a branded product, which carries a significantly higher cash price. Anyone mid-treatment should confirm their current prescription status directly with the platform before their next refill.
Can Ro Body actually get GLP-1s approved through insurance, or is the prior-auth support mostly symbolic?
Ro’s in-house prior-authorization team handles the documentation and insurer communication on the patient’s behalf, which is more than most telehealth services offer. Results depend on your specific plan and PBM. It does not guarantee approval, but the support is a real structural advantage over platforms that hand you a denial letter and stop there.
Is there any meaningful difference between compounded tirzepatide from a service like HealthRX versus branded Zepbound?
Compounded tirzepatide contains the same active molecule, but it is not FDA-approved and has not gone through the same manufacturing review as Zepbound. Pricing is dramatically different, roughly $149 versus $399 or more per month cash-pay. The clinical trial data cited for tirzepatide comes from branded-drug trials, so it does not directly apply to compounded versions.
Why does FormBlends cost so much more than Mochi or HealthRX if they all use compounded medications?
FormBlends publishes detailed third-party lab results, including HPLC purity figures and sterility data, per product. That testing infrastructure adds cost. It also serves patients in a clinical model that includes peptides beyond GLP-1s. Whether that premium is worth it depends on how much documented purity data matters to you personally, and whether you plan to use additional peptide therapies.
Sources
- FDA shortage list and compounding guidance, FDA.gov
- SURMOUNT-1 trial (tirzepatide), *The New England Journal of Medicine*, 2022, reporting 72-week outcomes for tirzepatide
- STEP 1 trial (semaglutide), *The New England Journal of Medicine*, 2021, reporting 68-week outcomes for semaglutide
- Novo Nordisk settlement announcement, March 9, 2026, company press release
- LillyDirect orforglipron launch details, Eli Lilly investor and press releases, April 2026
- LegitScript public certification database, LegitScript.com